This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [01.11.2019] – [General research on aging] sallieq | home:food:aim_health:aging [02.11.2019] – [with additional studies] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== | + | ====== |
Summary of research on aging and Olmesartan | Summary of research on aging and Olmesartan | ||
Line 7: | Line 7: | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
- | |||
- | | ||
- | |||
- | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
| | ||
The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
+ | |||
+ | | ||
The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | ||
- | Therapeutic and supratherapeutic | + | Therapeutic and supratherapeutic |
+ | |||
+ | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
==== General research on aging ==== | ==== General research on aging ==== | ||
- | Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, recurrent falls, and injurious falls. (({{pubmed> | + | When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. |
- | A number of meta-analyses | + | These articles |
==== Some of the documented protective effects of ARBs ==== | ==== Some of the documented protective effects of ARBs ==== | ||
| | ||
Line 110: | Line 111: | ||
=== Long term treatment === | === Long term treatment === | ||
- | Data suggest 40 & 80 mg olmesartan | + | |
// | // | ||
{{tag> | {{tag> | ||